The case study involves a patient presenting middle cerebral artery thrombosis, related to a severe vasospasm following subarachnoid hemorrhage due to aneurysm rupture. The patient was treated initially by surgical clipping of the left middle cerebral artery aneurysm. After surgery, the neurological status of the patient was normal. Six days later, the patient presented right hemiplegia and aphasia that were related to the proximal left middle cerebral artery thrombosis. Despite recent open-skull surgery, in situ thrombolysis using urokinase and antiplatelet antibodies (abciximab) was performed. The thrombosed artery was reopened and a severe vasospasm was observed. The vasospasm was treated by transluminal angioplasty. No intracranial hemorrhage was noted after thrombolysis and angioplasty, whereas subcutaneous hemorrhage around the scalp incision was observed. The patient recovered from motor and language impairment. The only long-term symptom was a mild dysorthographia. Balance of risk/benefit is discussed for such aggressive thrombolytic therapy. In this particular case, effectiveness and uneventful use of abciximab was demonstrated despite very recent brain surgery that was considered a formal contra-indication for the use of such a powerful thrombolytic drug.
Summary
The case study involves a patient presenting middle cerebral artery thrombosis, related to a severe vasospasm following subarachnoid hemorrhage due to aneurysm rupture. The patient was treated initially by surgical clipping of the left middle cerebral artery aneurysm. After surgery, the neurological status of the patient was normal. Six days later, the patient presented right hemiplegia and aphasia that were related to the proximal left middle cerebral artery thrombosis. Despite recent open-skull surgery, in situ thrombolysis using urokinase and antiplatelet antibodies (abciximab) was performed. The thrombosed artery was reopened and a severe vasospasm was observed. The vasospasm was treated by transluminal angioplasty. No intracranial hemorrhage was noted after thrombolysis and angioplasty, whereas subcutaneous hemorrhage around the scalp incision was observed. The patient recovered from motor and language impairment. The only long-term symptom was a mild dysorthographia. Balance of risk/benefit is discussed for such aggressive thrombolytic therapy. In this particular case, effectiveness and uneventful use of abciximab was demonstrated despite very recent brain surgery that was considered a formal contra-indication for the use of such a powerful thrombolytic drug.
Vessel thrombosis is an exceptional complication of cerebral vasospasm. In the early hours, intra-arterial thrombolysis may be considered, but recent intracranial surgery is usually an exclusion criterion to performing thrombolysis. We report the case of a patient who underwent thrombolysis and angioplasty in the postoperative period to treat this complication of vasospasm.
Case Report
A 36-year-old woman was admitted to the neurosurgical intensive care unit (NICU) for a subarachnoid hemorrhage (SAH). The patient did not have any neurological deficit (grade I in the classification of the World Federation of Neurological Surgeons) and the CT scan showed a diffuse SAH (Fischer grade Ill). An emergency cerebral angiography disclosed a left middle cerebral artery (MCA) aneurysm located on the MCA bifurcation. The patient underwent a difficult but uneventful operation the same day for clipping of the aneurysm. Three days later, the patient's neurological status was normal. Cerebral blood flow velocities in the middle cerebral arteries (Vmca) measured by transcranial Doppler (TCD) were within normal limits (left side 72 cm.s-l, right side 68 cm.s l). The patient was discharged from the NICU under treatment with oral nimodip- ine. The CT-scan showed hypodense areas involving mainly the left cortical structures of the temporal pole, the superior temporal gyrus, the insula and the posterior part of the putamen (figure 1). Twenty-four hours later, TCD examination revealed a rise in the left Vmca (Left side 106 cm.s-l, right side 70 cm.s-!) without any clinical deterioration. The patient was again admitted to the NICU to begin intravenous nimodipine and volume expansion. The next day, the left Vmca was 120 cm.s-! and a "triple H therapy" (hypervolemia, hemodilution and hypertension) was started.
The next day at 6:30 a.m., the patient presented sudden right-sided hemiplegia and total aphasia. Volume expansion and increase in blood pressure did not improve the neurological status. No signal in the left MCA could be recorded by TCD examination. At 10.30 a.m., cerebral angiography under general anesthesia disclosed complete thrombosis of the proximal left MCA (figures 2-3). After discussion between the neurosurgeon, neuroradiologist, neuroanesthesiologist, and with the family's informed consent, it was decided to perform arterial thrombolysis. A microcatheter (Rapid tran-sit@ , Cordis endovascular systems, Miami Lakes ,USA) was positioned in the thrombus to infuse 300000 UI urokinase in 20 minutes followed by attempts at mechanical disruption of the clot using the microguide wire.
These treatments were unsuccessful and abciximab (ReoPro® , Centocor, Eli Lilly, France) (0.25 mg.kg-! in 3 minutes) was infused in situ The patient returned to the NICU under treatment with nimodipine, dopamine, heparin and sedation. After stopping sedation, the trachea of the patient was extubated. A few hours later, the patient began to recover from her right-sided hemiplegia. Seven days later, there was only a moderate hemiparesis and the pa-tient was able to speak spontaneously but slowly and laboriously. eT-scan and MRI follow up did not show any new intracerebral hem orrhage nor new hypodensity. Two months later, there was no longer any motor deficit and the patient suffered only minor impairment in writing (dysorthographia).
Discussion
Intra-arterial thrombolysis of cerebral arteries has demonstrated a benefit in the first six hours after an ischemic stroke 1. However, intracranial hemorrhage within 24 hours of admission occurred in 35% of the patients after thrombolysis compared to 13 % in the conventional treatment group. This increased risk of early intracranial hemorrhage is the reason why recent intracranial surgery is an exclusion criterion in thrombolytic trials for ischemic stroke. We thoroughly discussed the risk versus benefit ratio of thrombolysis in this patient. Aphasia and hemiplegia is a devastating condition in a young woman. The neurosurgeon considered the risk of cerebral bleeding low because surgery had been strictly confined to the subarachnoid space without any cerebral tear. If a subarachnoid hemorrhage had occurred again due to rupture of intracranial hemostasis, it seemed possible to operate the patient again to drain the hematoma. Nevertheless, the risk of bleeding after surgery should not be neglected. The appearance of a new subcutaneous hematoma in the surgical field after the neuro- Hyperselective injection during fibrinolysis (Urokinase and Reopro). Note that the maximum stenosis related to the vasospasm is located 5 mm proximal to the surgical clip. radiologic procedure showed the precariousness of surgical hemostasis. Treatment with heparin after thrombolysis may be controversial because . it increases the risk of intracranial bleeding z: But the attempts at mechanical disruption of the clot and balloon angioplasty certainly induced a trauma to the vessel wall, which increased the thrombotic risk. Abciximab was considered after failure of recanalization of the vessel by urokinase alone. Abcix-0. Levrier imab is a chimeric antibody to the human platelet glycoprotein lIb/IlIa (GP lIb/IlIa) receptor which inhibits the binding of fibrinogen to platelets and thus platelet aggregation. GP llb/Ill ab inhibitors combined with plasminogen activators increase the potential for initial thrombolysis, the recanalization rate and decrease the risk of re occlusion during coronary thrombolysis or angioplasty 3,4 . A successful treatment with abciximab after failure of re-canalization of the basilar artery with urokinase has also been described 5. The most serious adverse effect of the drug is bleeding. In a prospective randomized trial on high-risk coronary angioplasty, the rate of major bleeding was twice as high in the abciximab treated group than in the placebo treated group 6. The risk was certainly significant in this patient who suffered postoperative cerebral ischemia. There is only limited experience with GP lIb/IlIa in- hibitors in the neurological field but a doubleblind, placebo-controlled study showed the safety of abciximab infused within 24 hours after ischemic stroke onseC. In that study, asymptomatic brain parenchymal hemorrhages were detected in 7% of abciximab treated patients compared to 5% in the placebo group. These preliminary data suggest that GP IIblIIIa inhibitors are probably safe within 24 hours after an ischemic stroke and may improve the recanalization rate after fibrinolysis. But we did not give the patient abciximab or aspirin or ticlopidine after the procedure to limit the risk of hemorrhage 8. Transluminal angioplasty was performed because there was a severe stenosis of the vessel, which in our opinion was responsible for the thrombosis. Although the superiority of angioplasty over medical management for cerebral arterial spasm has not been demonstrated by prospective controlled trials, many reports show that it is an effective treatment leading to an increase in cerebral blood flow and significant clinical improvement 9-11 . The association of thrombolysis and angioplasty for acute occlusion of intracranial arteries related to atherosclerotic disease has been reported in a study on 13 patients with good technical and clinical results 12 . In conclusion, we describe the association of urokinase, abciximab and angioplasty for the treatment of middle cerebral artery thrombosis five days after surgery for clipping of a ruptured intracranial aneurysm with a good outcome. The potential benefit of this therapeutic management should be weighted against the risk of intracranial bleeding, requiring careful patient selection.
